Medical oncologist, Mark Scholz, MD, answers questions all about immune therapies for prostate cancer. Topics include Provenge (Sipuleucel-T), Keytruda (Pembrolizumab), CAR T-cell therapy, and Leukine (Sargramostim).
0:08 What is immunotherapy in prostate cancer and how does it work?
1:23 Does Provenge have any side effects?
1:44 You've had ten years of experience treating patients with Provenge; how effective has it been in your patients?
3:02 Do you believe in giving Provenge to active surveillance patients? Is it approved for that use?
3:58 Can you explain how Keytruda works in prostate cancer?
5:41 How many patients have you treated with Keytruda and what success have you had with it?
6:15 When do you think Keytruda will get approved for prostate cancer?
6:40 If someone is interested in Keytruda, can any oncologist get them the medication?
7:02 What is CAR T-cell therapy and how will it affect future treatment?
7:59 What is Leukine, how does it work, and what is the side effect profile?
Don’t know your stage? Take the quiz: Visit www.prostatecancerstaging.org
To learn more about prostate cancer visit www.pcri.org
To receive the latest updates on prostate cancer and the PCRI, sign up for our online newsletter here: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
The information on the Prostate Cancer Research Institute's KZitem channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.
#ProstateCancer #Prostate #MarkScholzMD
Негізгі бет Immunotherapy in 2022: Provenge, Keytruda, Car-T, and Leukine for Prostate Cancer | Mark Scholz, MD
Пікірлер: 25